Immucor Announces Health Canada Approval For NEO Iris™; Next Generation, Fully Automated Instrument For Transfusion Medicine
Highest throughput for immunohematology now powered with clearer results for brilliant performance
Norcross, GA (GLOBE NEWSWIRE) - Immucor, Inc., a global leader in transfusion and transplantation diagnostics, today announced that its next generation, fully automated NEO® instrument, NEO Iris™, received approval by Health Canada. NEO Iris, Immucor’s sixth generation immunohematology instrument, underscores Immucor’s unprecedented decades-long commitment to safely and fully automate the blood bank. NEO Iris has the broadest test menu for mid- to high-volume, high-throughput blood testing performed in hospitals, donor centers and clinical reference laboratories.
“Our automation solution combined with the sensitivity of our Capture® technology, which identifies antibodies sooner than alternative technologies, provides laboratorians with confidence in the results they are producing for physicians and their patients,” said Keith Chaitoff, Immucor’s Chief Marketing Officer. Adds Christie Otis, Vice President, Transfusion Franchise and Global Customer Programs, “When labs perform safer, faster types, screens and identifications, it means they can get the best matched blood to patients who need it. Immucor understands that when patient care is on the line, every test result counts.”
Since 1998, Immucor has been a leader in automating the blood bank. The NEO instrument family has supported high quality transfusion medicine laboratories since 2010 with a footprint of more than 1,000 placements worldwide (including over 100 NEO Iris instruments outside the United States).
NEO Iris brings the following features to laboratories worldwide:
|
[Accuracy] |
Complementing highly sensitive Capture technology, the NEO Iris’s enhanced reader module provides clearer, real-time results and easy on-screen verification; |
|
[Productivity] |
Dynamic speed, workflow and resource handling support true continuous access to add samples (up to 224 at one time) or resources anytime; |
|
[Flexibility] |
Remarkable flexibility for STAT priority functionality for every sample supports the way work flows within each unique laboratory environment; and |
|
[Performance] |
A broad test menu with high productivity for both donor and patient testing allows automation for up to 60 types and screens per hour. |
A Total Solution - Built-in Integration for Data Management and Support
NEO Iris and all Immucor transfusion solutions integrate with the Company’s comprehensive data management software solution, ImmuLINK®, to aggregate all serology and molecular test results, generating a single report with a complete donor or patient testing history. NEO Iris also includes a bi-directional interface with blud_directSM, Immucor’s 24/7 remote diagnostics and instrument support solution.
NEO Iris is part of Immucor’s commitment to immunohematology automation. As an industry leader with over 2,500 instrument placements worldwide, Immucor’s innovative technologies provide high-quality, high-performance and scalable solutions to meet the operational needs of blood banks, donor centers and labs, regardless of size or volume. Immucor’s total solution extends beyond instrumentation to include serology, molecular and platelet specialty products, dedicated customer support, field service engineers, LEAN-certified consulting services and an educational resource network.
Request a Demonstration
To schedule a demonstration of NEO Iris or any Immucor solution, Immucor clients may contact their Blood Bank Business Manager or call us at 855.IMMUCOR (855.466.8267). For more information about Immucor products or to learn the regulatory status of our products in your country, please contact your local Immucor representative or visit www.immucor.com.
About Immucor
Founded in 1982, Immucor is a global leader in transfusion and transplantation diagnostics that facilitate patient-donor compatibility. Our mission is to ensure that patients in need of blood, organs or stem cells get the right match that is safe, accessible and affordable. With the right match, we can transform a life together. For more information on Immucor, visit www.immucor.com.
© 2019 GlobeNewswire, Inc. All Rights Reserved.
Source: Immucor, Inc.